Результаты поиска

Pathologic flail chest complicating multiple myeloma.

Pathologic flail chest complicated the initial presentation of multiple myeloma in two patients. Both had severe hypercalcemia and diffuse bone disease. Atelectasis and pulmonary edema preceded the appearance of flail chest in one patient; atelectasis complicated the flail chest in the second patient and increased the severity of the flail. Both were treated with radiotherapy and chemotherapy. However, delay in stabilizing the first patient's chest wall with positive airway pressure was followed by extension of the flail chest and irreversible respiratory failure. On the other hand, prolonged …

Osteogenesis imperfecta associated with multiple myeloma.

In a case of osteogenesis imperfecta with multiple fractures already from childhood, myelomatosis was diagnosed at the age of 52 years because of a serum M-component (IgG, lambda), Bence Jones proteinuria, myeloma cells in the bone marrow, and osteolytic skeletal lesions. She died 10 months later. A partial postmortem examination of a larger bone lesion confirmed the diagnosis.

Monoclonal gammapathy, multiple myeloma and cancer.

Seventeen cancer patients with monoclonal gammapathy on serum protein electrophoresis are described. Thirteen of these patients were proved to have multiple myeloma, while four patients had "benign" monoclonal gammapathy. In all the cases where bone marrow aspiration was done, an increase in plasma cells was revealed. A majority of the myeloma patients had osteolytic lesions, while all the patients with "benign" monoclonal gammapathy had normal bone survey. A relationship between the solid tumors and monoclonal gammapathy is discussed. The difficulty of detecting multiple myeloma in patients w…

Multiple myeloma involving the lacrimal gland.

The third case of myeloma presenting as a lacrimal gland tumor is reported. The lesion was originally diagnosed as a solitary extramedullary myeloma, but on follow-up, the patient was seen to develop other myelomas. This case illustrates the necessity for careful follow-up of patients with solitary myelomas, even in the absence of bone marrow pathology, for the solitary extramedullary myeloma may represent an early stage in the development of multiple myeloma.

Acute renal failure in multiple myeloma.

1. The clinical manifestations, laboratory data and renal histologic features of acute renal failure occurring in 14 patients with multiple myeloma are reviewed and contrasted with the data from 29 previously reported cases. 2. Whereas other reports have stressed the role of intravenous pyelography and dehydration in the development of acute renal failure in multiple myeloma, the most common etiologic factor in our experience was hypercalcemia (7 patients). Other factors included potentially nephrotoxic antibiotics (3 patients) and volume depletion (2 patients). Intravenous pyelography could b…

[Diagnosis and Laboratory Follow-Up of Patients with Multiple Myeloma: Guidelines from the Portuguese Multiple Myeloma Group].

Multiple myeloma is a neoplasm of plasma cells that in most cases is associated with the secretion of monoclonal immunoglobulins and can involve multiple organs. Its timely diagnosis is essential to limit or avoid irreversible damage and dysfunction of target organs. Appropriate initial stratification of patients allows for optimization in the selection and sequence of therapy, as well as proper follow-up during treatment and monitoring, impacting survival. These laboratory guidelines from the Portuguese Multiple Myeloma Group provide recommendations for the diagnosis and laboratory follow-up …

Ассоциация " Демографические отношения пациентов " и " Смолодинг " ( " Multieloma Progressing to Multieloma: A SEER-Medicare Data Analysis).

В то время как было разработано несколько моделей стратификации риска для запятнания множественных миелом (ШМ) симптоматическим множественным миелом (ММ), связь между демографическими показателями пациентов, такими, как раса, пол и возраст, и продвижением SMM, не вполне понятна. МЕТОДЫ: Анализ данных наблюдения, эпидемиологии и конечных результатов (SEER)-Mediare, мы применили ранее разработанный алгоритм для идентификации пациентов с диагнозом SMM между 2007 и 2019. Мы использовали нераковых пациентов из 5% - выборочная выборка бенефициаров программы " Медикэр " в качестве контрольн

Совпадение в аннотации оригинала
BACKGROUND: While several risk stratification models for smoldering multiple myeloma (SMM) to symptomatic multiple myeloma (MM) progression have been developed, the association between patient demographics, such as race, gender, and age, and SMM progression is not well understood. METHODS: Analyzing surveillance, epidemiology, and end results (SEER)-Medicar…

Circulating Multiple Myeloma Cells (CMMCs) as Prognostic and Predictive Markers in Multiple Myeloma and Smouldering MM Patients.

In recent years, liquid biopsy has emerged as a promising alternative to the bone marrow (BM) examination, since it is a minimally invasive technique allowing serial monitoring. Circulating multiple myeloma cells (CMMCs) enumerated using CELLSEARCH® were correlated with patients' prognosis and measured under treatment to assess their role in monitoring disease dynamics. Forty-four MM and seven smouldering MM (SMM) patients were studied. The CMMC medians at diagnosis were 349 (1 to 39,940) and 327 (range 22-2463) for MM and SMM, respectively. In the MM patients, the CMMC count was correlated wi…

Outcome of Multiple Myeloma Patients With Hepatitis B Surface Antigen: Korean Multiple Myeloma Working Party 2103 Study.

BACKGROUND: Hepatitis B virus reactivation (HBVr) is a well-known complication of systemic chemotherapy for particularly hematologic malignancies in HBV carriers. We performed a multicenter retrospective study to investigate the incidence and risk factors of HBVr in patients with hepatitis B surface antigen (HBsAg)-positive multiple myeloma (MM). METHODS: We included 123 patients with HBsAg-positive MM who had received systemic therapy. The primary objective of the study was to evaluate the incidence of HBVr in patients with HBsAg-positive MM. RESULTS: The median age was 59 years, and 72 pat…

Immunoglobulin M Multiple Myeloma: Case Report of a Rare Variant of Multiple Myeloma with Diagnostic and Treatment Challenges.

Immunoglobulin M (IgM) multiple myeloma (MM) is an exceptionally rare plasma cell malignancy, representing <0.5% of all MM cases. The diagnosis presents significant challenges due to overlapping clinical features with Waldenström macroglobulinemia and other IgM-producing lymphoproliferative disorders. We report a 64-year-old female who presented with a 3-week history of persistent lower back pain. Initial laboratory evaluation revealed mild anemia (hemoglobin 9.2 g/dL), markedly elevated serum IgM levels (5,070 mg/dL), and a prominent M-spike (3.09 g/dL) on serum protein electrophoresis. Immun…

Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma.

PURPOSE: The diagnosis of smoldering multiple myeloma (SMM) primarily relies on clinical features such as plasma cell involvement, immunoglobulin protein levels, and end-organ damage. However, as early intervention becomes a priority, the role of genomic features in differentiating risk is gaining attention. METHODS: This study analyzed next-generation sequencing data from 224 precursor condition samples with 51 patients having paired SMM and multiple myeloma (MM) and 1,779 samples from newly diagnosed MM to identify genomic features linked to progression in SMM and those with a low-risk nonp…

Prevention Of Skeletal Related Events In Multiple Myeloma: Focus On The RANK-L Pathway In The Treatment Of Multiple Myeloma.

More than 90% of patients with multiple myeloma (MM) have osteolytic bone lesions which increase the risk of skeletal-related events (SRE). The cytokine milieu in the bone marrow microenvironment (BMME) of MM plays a key role in myeloma bone disease by impairing the balance between osteoclastogenesis and osteoblastogenesis. This is orchestrated by the malignant plasma cell (MPC) with the ultimate outcome of MPC proliferation and survival at the expense of excess osteoclast activation resulting in osteolytic bone lesions. Prevention of SRE is currently accomplished by the inhibition of osteocla…

miR-100-5p is upregulated in multiple myeloma and involves in the pathogenesis of multiple myeloma through targeting MTMR3.

OBJECTIVES: MicroRNA (miRNA) is a kind of highly conserved single-stranded small endogenous non-coding RNA associated with multiple diseases, particularly cancer. The miRNAs expression profile in multiple myeloma (MM) has been barely elucidated. METHODS: The miRNAs expression profiles in bone marrow plasma cells of 5 MM individuals and 5 iron-deficiency anemia volunteers were analyzed using RNA-sequencing. Quantitative polymerase chain reaction (QPCR) was performed to validate the expression of selected miR-100-5p. The biological function of selected miRNA was predicated by bioinformatics ana…

Comparison of clinical and laboratory characteristics of nonsecretory multiple myeloma and secretory multiple myeloma in a tertiary care hospital.

INTRODUCTION: Nonsecretory multiple myeloma (NSM) is a rare variant of multiple myeloma, accounting for approximately 1%-5% of all reported cases. We compared the characteristics of NSM and secretory multiple myeloma (SM). METHODS: We examined clinical and laboratory characteristics of 17 patients diagnosed with NSM and 40 patients diagnosed with SM. NSM was diagnosed based on findings of bone marrow (BM) examination, serum-free light chain (sFLC) assay, flow cytometric (FCM) immunophenotyping, chromosomal analysis, and imaging studies. RESULTS: No patient with NSM had hypercalcemia or renal…

Multiple mechanisms contribute to acquired TRAIL resistance in multiple myeloma.

Multiple Myeloma (MM) prognosis has recently improved thanks to the incorporation of new therapies to the clinic. Nonetheless, it is still a non-curable malignancy. Targeting cancer cells with agents inducing cell death has been an appealing alternative investigated over the years, as is the case of TRAIL, an agonist of DR4 and DR5 death receptors. This pathway, involved in apoptosis triggering, has demonstrated efficacy on MM cells. In this research, we have investigated the sensitivity of a panel of MM cells to this agent and generated TRAIL-resistant models by continuous culture of sensitiv…

Improved Outcomes of Myeloma Cast Nephropathy in Newly Diagnosed Multiple Myeloma With Modern Anti-Myeloma Therapies.

Myeloma cast nephropathy (MCN) is a driver of renal failure in newly diagnosed multiple myeloma (NDMM) and has been historically associated with increased early mortality. Since patients with moderate to severe renal insufficiency are typically excluded from trials, we performed a retrospective study to characterize modern-era outcomes in MCN. We reviewed 274 consecutive NDMM patients from 2017 to 2023 at an academic center and identified 46 patients (16.8%) with MCN. Among them, 96% had received bortezomib and 67% anti-CD38+ monoclonal antibody in frontline therapy. As per the International M…